Aligos Therapeutics appoints Bridget Martell, M.D. to Board of Directors

Aligos Therapeutics, Inc.

Dr. Martell appointed as Class III director; term expires at 2023 annual meeting.
She receives $35,000 annual retainer (prorated) and initial option grant of 30,000 shares.
Board size increased from seven to eight directors.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Bridget Martell

Class III director

ALGS · Aligos Therapeutics, Inc.

Effective: 2021-11-16
Filed: November 18, 2021, 6:59 PM ET

appointed Bridget Martell, M.D., to the Board to fill the newly created directorship resulting from the increase in the number of authorized directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bridget Martell was appointed as Class III director at Aligos Therapeutics, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

appointed Bridget Martell, M.D., to the Board to fill the newly created directorship resulting from the increase in the number of authorized directors.

View on SEC.gov

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-333831

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.